title: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Willett
authors.forename: Yves
authors.initials: Y
authors.lastname: Boucher
authors.forename: Dan G
authors.initials: DG
authors.lastname: Duda
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: di Tomaso
authors.forename: Lance L
authors.initials: LL
authors.lastname: Munn
authors.forename: Ricky T
authors.initials: RT
authors.lastname: Tong
authors.forename: Sergey V
authors.initials: SV
authors.lastname: Kozin
authors.forename: Lucine
authors.initials: L
authors.lastname: Petit
authors.forename: Rakesh K
authors.initials: RK
authors.lastname: Jain
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Chung
authors.forename: Dushyant V
authors.initials: DV
authors.lastname: Sahani
authors.forename: Sanjeeva P
authors.initials: SP
authors.lastname: Kalva
authors.forename: Kenneth S
authors.initials: KS
authors.lastname: Cohen
authors.forename: David T
authors.initials: DT
authors.lastname: Scadden
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Fischman
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Clark
authors.forename: David P
authors.initials: DP
authors.lastname: Ryan
authors.forename: Andrew X
authors.initials: AX
authors.lastname: Zhu
authors.forename: Lawrence S
authors.initials: LS
authors.lastname: Blaszkowsky
authors.forename: Paul C
authors.initials: PC
authors.lastname: Shellito
authors.forename: Mari
authors.initials: M
authors.lastname: Mino-Kenudson
authors.forename: Gregory Y
authors.initials: GY
authors.lastname: Lauwers
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D015415:Biomarkers; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D011379:Prognosis; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy*; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D000068258:Bevacizumab; D005472:Fluorouracil